NMDAR Antagonist Combination Therapy for Depression With Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression, particularly major depression, have limited efficacy and are associated with significant side effects such as anxiety and increased suicidality, with combinations of antidepressants not providing superior outcomes and often worsening these issues.
Innovation Solution
Combining ketamine agents with specific antidepressant agents, including racemic ketamine, S-ketamine, or R-ketamine, to treat depressive disorders with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antidepressant treatments are used, then depression symptoms are treated, but anxiety and suicidality side effects increase
Solution Approach 1:
The patent introduces NMDAR antagonists as intermediary substances that mediate between the antidepressant treatment and the patient's neural pathways. These antagonists block NMDA receptors to produce rapid antidepressant effects while reducing the harmful side effects of traditional antidepressants, acting as a bridge that achieves treatment goals without the adverse consequences.
Solution Approach 2:
The patent changes the pharmacological parameters by introducing NMDAR antagonists with specific binding characteristics to the NMDA receptor. This parameter change in the treatment approach - using compounds with specific affinity for NMDA receptors - produces different therapeutic outcomes compared to traditional antidepressants, achieving efficacy while minimizing anxiety and suicidality side effects.
2Adaptability or versatility
If combinations of antidepressants are used, then treatment coverage is increased, but side effects are worsened
Solution Approach 1:
The patent merges traditional antidepressant therapy with NMDAR antagonist therapy into a combined treatment approach. This combination leverages the strengths of both treatments - the adaptability and versatility of antidepressants for various depression types - while the NMDAR antagonist component reduces the cumulative side effects that would result from using multiple antidepressants alone.
3Stability of the object's composition
If traditional antidepressant regimens are used, then treatment is maintained, but efficacy is limited
Solution Approach 1:
The patent applies preliminary action by introducing NMDAR antagonists at the beginning of treatment or in combination with established antidepressant regimens. This preliminary intervention with NMDAR antagonists provides rapid initial efficacy that complements the slower-acting traditional antidepressants, thereby improving overall treatment efficacy while maintaining the stability and continuity of the established treatment regimen.
Data Source
AI summary
Provided herein are combination treatments for use in treatment of NMDAR antagonist-responsive disorders such as depression, and which can simultaneously alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications, thereby enabling continued and improved antidepressant and antipsychotic treatment. Methods for treatment of NMDAR-antagonist responsive disorders while simultaneously reducing medicament side effects, particularly anxiety, akathisia, and associated suicidality are also described herein.